The US Food and Drug Administration(FDA) recently approved the first drug in a new class of osteoporosis-fighting medications known as RANKL, or RANK ligand inhibitors. These medications work decrease bone loss in a way that is different from other osteoporosis medications (such as Fosamax, Boniva, etc.)
The newly approved drug, denosumab (Prolia), is an injectable medication derived from a synthetic antibody. It is approved by the FDA for treating postmenopausal women with osteoporosis and other patients who have failed or couldn't tolerate other medications.
To learn more, call 260-9322.